Viking Therapeutics, Inc. (VKTX)

Market Cap	3.97B +34.3%
Revenue (ttm)	n/a
Net Income	-359.64M
EPS	-3.19
Shares Out	115.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,735,100
Open	35.25
Previous Close	34.95
Day's Range	33.85 - 35.46
52-Week Range	20.41 - 43.15
Beta	0.82
Analysts	Strong Buy
Price Target	88.00 (+156.86%)
Earnings Date	Apr 22, 2026

About VKTX

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2015
• Employees: 53
• Stock Exchange: NASDAQ
• Ticker Symbol: VKTX
• Website: https://www.vikingtherapeutics.com

Analyst Summary

According to 10 analysts, the average rating for VKTX stock is "Strong Buy." The 12-month stock price target is $88.0, which is an increase of 156.86% from the latest price.

Price Target

$88.0

(156.86% upside)

Analyst Consensus: Strong Buy